The FDA expects organizations to have full visibility and control over their processes
Publisher: Dassault Systèmes BIOVIA
Access this content
Your content has been opened.
The FDA expects organizations to have full visibility and control over their processes has been emailed to . Entered the wrong email?
Don't see the content in your inbox?
Make sure to check your spam and other messages folders.
Can't get to your email right now?
To complete your registration and access this content, enter the sign-in code sent to your email.
Please enter a valid verification code.
Code sent to:
Register to access this content
By accessing content on the Pharmaceutical Manufacturing Resource Directory you agree to our Terms of Service and Privacy Policy; and, you acknowledge that your information may be shared with the content publisher.
Expectations include: • Understanding products and processes in order to implement Quality by Design (QbD) into product development • Delivery of quality metrics for risk-based inspection schedules as proposed by a new quality metrics program • Shared responsibility for products manufactured by their Contract Manufacturing Organizations (CMOs) • Drive improvements in manufacturing technology, product quality and safety - reducing recalls and mitigating drug shortages
Similar content you might be interested in
